MEDTECH

Carl Zeiss Meditec and Precise Bio Announce Partnership in the Development and Commercialization of Tissue-Based Implants for Ophthalmology

Precise Bio | July 19, 2022 | Read time : 08:11 min

Carl Zeiss
Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.                                                      

Under the terms of the agreement, Carl Zeiss Meditec will invest in Precise Bio and fund the further development of Precise Bio's two cornea transplant products and has exclusive worldwide commercialization rights for these products. Financial terms were not disclosed.

"This investment in Precise Bio is expected to complement our leading portfolio of cataract and corneal refractive workflow solutions. The technology has the potential to advance treatment options for corneal disease, as well as for elective procedures – furthering enabling optimization of patient care."

Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of the Digital Business Unit for Carl Zeiss Meditec

"We are very excited with this partnership that builds on our successful, ongoing collaboration with ZEISS for the development of corneal tissues to address unmet needs in the field of ophthalmology," stated Aryeh Batt, Co- Founder and CEO of Precise Bio. "This strategic agreement leverages ZEISS' global leadership in ophthalmology and Precise' innovative and unique 4D bio-fabrication platform technology. We are confident that the synergy between the two companies will allow us to develop breakthrough solutions for recovering patients' eyesight, bringing hope to hundreds of millions of patients worldwide."

Precise Bio combines engineering, biomaterials, cell technology, bioengineering, and 3D printing into an unparalleled 4D bio-fabrication platform for transplantable organs and tissues. The Company's proprietary platform technology allows to fabricate tissues by 'printing' cells in a single-cell resolution and spatial accuracy, enabling complex organoid constructs with both structural integrity and long-term cell viability. Overcoming multiple technology challenges, Precise Bio's 4D bio-fabrication technology allows to reliably scale up tissue engineering for clinical use, and produce large quantities in a reproducible, quality controlled and cost-effective process. Precise Bio's ophthalmological pipeline consists of three products, the two cornea products that are the subject of the collaboration with Carl Zeiss Meditec and a retinal implant for age-related macular degeneration, all of which demonstrated successful results in animal models. The Company's ophthalmological products address global markets exceeding $10 billion annually.

Bio-fabricated tissues comprised of human cells and natural materials, mimicking the anatomical structure and natural tissue components, can replace damaged or diseased tissue, substitute for donor tissue in cases where there is lack of tissue or solve unmet therapeutic needs.

About ZEISS
Carl Zeiss Meditec AG AX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,531 employees worldwide, the Group generated revenue of €1,646.8m in fiscal year 2020/2.

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research ore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

About Precise Bio
Precise Bio develops regenerative medicine therapies that can transform patient care across a wide range of medical indications. Precise Bio's proprietary, break-through 4D bio-fabricating platform overcomes limitations of existing extrusion and ink-jet printers and paves the way for fabricating clinically viable tissues and organs. The Company's initial product pipeline is focused on ophthalmology and includes fabricated functional corneal grafts, intrastromal lenticules for treating keratoconus and vision correction, and a retinal implant for age-related macular degeneration. The Company also has earlier R&D programs to address unmet needs in additional medical indications, which are limited by the number of available donor tissues and organs, or where today's critical health problems can be solved using Precise Bio's naturally-based, hyper-accurate technology.

Spotlight

Apoptosis is a highly regulated and critical homeostatic process in multicellular organisms. Aberrations in this form of programmed cell death have been implicated in several pathological conditions including cancer, muscular atrophy, and autoimmune disease. The biochemical and morphological events underlying apoptosis include perturbations in mitochondrial membrane potential, death receptors on the cell surface, recruitment of adapter proteins, caspase activation, and condensation of chromatin along with nuclear fragmentation.

Spotlight

Apoptosis is a highly regulated and critical homeostatic process in multicellular organisms. Aberrations in this form of programmed cell death have been implicated in several pathological conditions including cancer, muscular atrophy, and autoimmune disease. The biochemical and morphological events underlying apoptosis include perturbations in mitochondrial membrane potential, death receptors on the cell surface, recruitment of adapter proteins, caspase activation, and condensation of chromatin along with nuclear fragmentation.

Related News

MEDTECH

TheraVet Announces Its Participation in the 2022 ESVOT Congress With 3 Scientific Communications

TheraVet SA | September 19, 2022

TheraVet a pioneering company in the management of osteoarticular diseases in pets, announced today its participation in the annual congress of the European Society of Veterinary Orthopaedics and Traumatology which will be held from 21 to 24 September at the Acropolis in Nice, France. With nearly 1000 participants, this event is the largest specialised congress in veterinary orthopaedics and traumatology in Europe, bringing together high-quality international speakers and therefore represents a prime showcase for the Company. ESVOT is chaired by Pr. Marc Balligand, who is also the President of the Scientific Advisory Board of TheraVet. About TheraVet SA TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris a with a US subsidiary in Texas. About BIOCERA-VET In close collaboration with an international scientific board, THERAVET® has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on extremely promising clinical results, this line offers the possibility of a better, more convenient and more efficient orthopedic surgery.

Read More

INDUSTRIAL IMPACT

Naveris Inc. Raises $51 Million to Advance Commercialization of NavDx

Naveris, Inc. | September 20, 2022

Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 million expansion of its Series A financing, bringing the total investment in Naveris to $51 million. The financing was led by Gurnet Point Capital, joined by TechU Ventures and BrightEdge, the impact and venture capital arm of the American Cancer Society. Naveris’ blood tests for earlier cancer detection use proprietary patented DNA fragmentomics technology to distinguish between viral DNA arising from cancers versus infection. Proceeds from this financing will be used to advance commercialization of NavDx, Naveris’ flagship blood test for the early detection of cancers caused by the human papillomavirus (HPV), and to generate the clinical data needed to expand into other cancer types and indications. “We are delighted to have the continued support of Gurnet Point Capital and TechU Ventures, and to welcome Alice Pomponio and the rest of the BrightEdge team, who collectively bring a deep understanding of both the oncology space and commercial-stage businesses. We founded Naveris on the belief that advances in molecular diagnostics will play a vital role in improving cancer outcomes. This new investment underscores NavDx’s commercial success and potential, and our experienced team’s ability to transform this vision into a reality for patients and oncologists.” Piyush B. Gupta, Ph.D., Naveris founder and Chief Executive Officer "Since our initial investment in 2020, we have been impressed by the Naveris team's vision and their ability to commercially execute on a differentiated strategy in the rapidly developing field of blood-based cancer detection,” said Travis Wilson, Partner at Gurnet Point Capital. “We are pleased to be providing additional capital to ensure that their transformative technology for early cancer detection will benefit as many patients as possible." “We could not be more excited to back Piyush and his team as Naveris works to increase access to diagnose, detect, and monitor viral cancers” said Alice Pomponio, BrightEdge Managing Director. “We understand the burden of HPV related cancers on patients. And we seek to build on the years of research and advocacy of the American Cancer Society to support the next generation of mission aligned companies reducing patient burden.” Along with Naveris' commercial activities, more than 25 medical institutions have partnered with the company to conduct clinical studies and trials utilizing its technology. The company has also partnered with biotechnology companies developing immunotherapies for HPV-related cancers. About Naveris, Inc. Founded in 2017, Naveris is a privately held biotechnology company with facilities in Massachusetts and North Carolina. The company’s mission is to improve outcomes for the millions of people at risk of developing viral cancers through novel molecular diagnostics that enable earlier cancer detection. Naveris’ clinical laboratory is certified for high complexity testing under CLIA, and is accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center. About Gurnet Point Capital Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives work closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.

Read More

CELL AND GENE THERAPY

Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers

Aktis Oncology | August 24, 2022

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225. "Given the breadth and depth of our emerging pipeline, securing robust isotope supply across all stages of development is critical. Each of our three partners are leaders in the field of nuclear innovation with strong reputations for production, operational experience, and technical capabilities. We believe these foundational relationships with such high-quality suppliers will ensure timely and efficient progression of our programs and ultimately, enable patient access to potentially life-saving therapies." Matthew Roden, PhD, President and Chief Executive Officer of Aktis Oncology The three agreements provide Aktis with a portfolio of suppliers that utilize varied techniques to produce high quality Actinium-225, and enhance the Company's ability to ensure just-in-time delivery of finished targeted radioconjugates to healthcare providers for administration to patients. NorthStar's approach to Actinium-225 production is to utilize non-uranium, electron accelerator-based production methods; Niowave builds and operates superconducting electron accelerators to produce Ac-225 and other radioisotopes, whereas TerraPower uses a Thorium-229 generator. These agreements are a part of broader ongoing efforts to build and enhance Aktis's supply access, radiomanufacturing and distribution capabilities. Aktis Oncology is creating precision targeting molecules to deliver Actinium-225 directly to cancer cells, thereby harnessing alpha radiation to treat commonly occurring cancers with limited treatment options, including breast, lung and colorectal cancers, and to improve standards of cancer care. Actinium-225's powerful alpha particle emissions potently kill cancer cells by inducing double strand DNA breaks to overcome acquired resistance to traditional chemotherapy, and potentially outperform the new generation antibody drug conjugates. About Aktis Oncology Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment. This approach would enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Read More